Innovative technologies aimed at reducing the risk of chronic kidney disease with comorbid pathology
Tashkent State Medical University, Tashkent, Uzbekistan.
Review
World Journal of Advanced Pharmaceutical and Life Sciences, 2025, 09(01), 009-15.
Article DOI: 10.53346/wjapls.2025.9.1.0034
Publication history:
Received 04 November 2025; revised on 12 December 2025; accepted on 15 December 2025
Abstract:
Chronic kidney disease (CKD) rarely occurs in isolation; its progression is accelerated by highly prevalent comorbidities such as diabetes, hypertension, cardiovascular disease, heart failure, and obesity, creating bidirectional vicious cycles that dramatically increase the risk of kidney failure, cardiovascular events, and mortality. Traditional risk-stratification tools based on eGFR and albuminuria fail to capture the dynamic, multimorbid nature of this population, resulting in late diagnosis and suboptimal preventive strategies. This state-of-the-art review examines cutting-edge technologies with proven or emerging potential to break these vicious cycles and reduce CKD risk in patients with comorbid pathology. We synthesize evidence across seven transformative domains: (1) artificial intelligence and machine-learning models that integrate multimodal data (electronic health records, imaging, omics) for superior long-term risk prediction and personalized therapeutic guidance; (2) wearable and implantable sensors enabling realureal-time physiological monitoring and closed-loop interventions; (3) integrated telemedicine and remote management platforms; (4) multiomics and pharmacogenomics for precision prevention; (5) bioengineered and regenerative approaches, including xenotransplantation, stem-cell-derived organoids, and bioartificial kidneys; (6) targeted drug-delivery systems and long-acting therapeutics; and (7) digital therapeutics for behavioral modification. Current randomized trials and real-world implementations demonstrate that these technologies can improve risk-factor control, slow eGFR decline, reduce hospitalizations, and delay dialysis initiation in high-risk multimorbid cohorts. Nevertheless, successful translation demands solutions for interoperability, regulatory harmonization, algorithmic bias, digital inequity, and sustainable reimbursement models. By converging nephrology, data science, bioengineering, and implementation science, these innovative technologies offer a realistic pathway toward proactive, personalized CKD prevention in the multimorbid patient of the 21st century. Coordinated multidisciplinary efforts are now required to move from promising pilots to scalable, equitable clinical reality.
Keywords:
Chronic Kidney Disease; Comorbidities; Artificial Intelligence; Wearable Sensors; Telemedicine; Precision Medicine; Bioartificial Kidney; Regenerative Medicine; Risk Stratification; Digital Health
Full text article in PDF:
Copyright information:
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0